DDInter1335 DDInter922
Omacetaxine mepesuccinate (formerly known as HHT or Homoharringtonine), is a cephalotaxine ester and protein synthesis inhibitor with established clinical activity as a single agent in hematological malignancies. Omacetaxine mepesuccinate is synthesized from cephalotaxine, which is an extract from the leaves of the plant, Cephalotaxus species. In October 2005, omacetaxine mepesuccinate received Orphan Drug designation from the EMEA for the treatment of chronic myeloid leukemia (CML). Then in March 2006, it received Orphan Drug status from the FDA for the treatment of CML. In November 2006, omacetaxine mepesuccinate, for the treatment of CML, was granted Fast Track designation by the FDA. Most recently, in October 2012, omacetaxine mepesuccinate was
Inappropriate growth of or self-directed antibody production by B-cells is the etiological underpinning of a variety of conditions, including the multiple sclerosis-like neurological condition neuromyelitis optica spectrum disorder (NMOSD).[A214283, A214286] Inebilizumab is a humanized afucosylated monoclonal IgG1 antibody directed against the broadly expressed B-cell surface antigen CD19. Inebilizumab is cytolytic, resulting in B-cell depletion and offering therapeutic benefit to patients suffering from NMOSD. Compared to the anti-CD20 antibody [rituximab], which is also used to treat NMOSD, inebilizumab has broader specificity.[A214280, A214289, A214292, A214295, A214298, A214301] Inebilizumab was granted FDA approval on June 11, 2020, for the treatment of anti-aquaporin 4 positive NMOSD patients. Given its mechanism of action and good safety profile, it may prove useful in the treatment of other conditions linked to autoimmune antibody production or B-cell malignancies.[A214280, A214295] On January 16, 2024, Iinebilizumab also received Health Canada approval for the same indication.
Omacetaxine mepesuccinate {u} (Compound) binds {v} (Gene) RPL3
Omacetaxine mepesuccinate {u} (Compound) upregulates {v} (Gene) DUSP8
Omacetaxine mepesuccinate {u} (Compound) downregulates {v} (Gene) B4GAT1
Omacetaxine mepesuccinate {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Rituximab
Omacetaxine mepesuccinate {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Risankizumab
Omacetaxine mepesuccinate {u} may lead to a major life threatening interaction when taken with {v} Indomethacin
Omacetaxine mepesuccinate {u} may lead to a major life threatening interaction when taken with {v} Avapritinib
Omacetaxine mepesuccinate (Compound) binds RPL3 (Gene)
Omacetaxine mepesuccinate (Compound) upregulates DUSP8 (Gene)
Omacetaxine mepesuccinate (Compound) downregulates B4GAT1 (Gene)
Omacetaxine mepesuccinate may cause a moderate interaction that could exacerbate diseases when taken with Rituximab
Omacetaxine mepesuccinate may cause a moderate interaction that could exacerbate diseases when taken with Risankizumab
Omacetaxine mepesuccinate may lead to a major life threatening interaction when taken with Indomethacin
Omacetaxine mepesuccinate may lead to a major life threatening interaction when taken with Avapritinib